Alopecia

Qing Yu Christina Weng, MD, shares insights into the drug's advancement following preliminary phase 1 findings.

The investigator in the clinical development program for deuruxolitinib shared data, patient populations to consider, and more in a recent interview.

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment.

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Results showed that the most common nail concerns associated with or independent of hair loss included pitting, ridging, and white spots.

A recent review suggested there may be a higher risk of AA development after COVID-19 vaccination in patients with a history of AA or thyroid dysfunction.

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

Maryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.

An analysis explored the feasibility of directing attention towards the thyroid receptor β as a pathway for creating novel medications to address androgenetic alopecia.

Researchers noted differences in microbial evenness, abundance composition, and functional prediction.

The trial reported complete hair regrowth for a number of participants, with 76% of a partial cohort meeting the primary endpoint of 30% improvement.

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

In a recent study, platelet-rich plasma not only increased hair regrowth but also rebalanced the scalp microbiome in patients with AGA.

James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.

The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.

The largest patient study across the continent found a direct link between the extent of hair loss and the negative impact on quality of life.

A recent study spotlights an opportunity for interdisciplinary collaboration between dermatologists and orthodontists.

This week’s collection of the latest dermatologic studies includes artificial intelligence in cutaneous lesions, dupilumab-induced acanthosis nigricans, aesthetic considerations for treating lesbian, gay, and bisexual patients, and monotherapies for male androgenetic alopecia.

These challenges may exacerbate racial inequities in care access and quality, according to a new study.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.

The data suggests that the medication, which targets specific cellular pathways, promotes hair regrowth in AA with minimal adverse effects.

Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.

In this week’s Pointers With Portela, the 208SkinDoc answers common hair loss questions.

The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.

Factors including disease duration, treatment response, and mental health were listed as crucial factors in severity and treatment.